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ABSTRACT
Objective: To improve dissolution rate of valsartan from solid dispersion system of valsartan and D(−) mannitol using co-grinding approach.
Methods: Valsartan solid dispersion with different ratio of D(−) mannitol (1:1; 1:3 and 1: 5) were prepared by co-grinding method. Solid state 
characterization of the solid dispersion system was evaluated in term of crystallographic properties (powder X-ray diffraction), thermal behavior 
(differential scanning calorimetry [DSC]) and morphology (scanning electron microscope). The profile of dissolution rate was examined using USP 
dissolution apparatus type I at a temperature of 37±0.5°C.
Results: Based on thermal analysis DSC and powder X-ray diffraction analysis, valsartan was transformed from semicrystalline phase to amorphous 
state as indicated by the disappearance of its melting endothermic peaks and the characteristic diffraction peaks. The in vitro dissolution rate study 
revealed that all solid dispersion system showed significant increase in dissolution rate compared with the intact valsartan.
Conclusion: Solid dispersion of valsartan with D(−) mannitol prepared by co-grinding technique has successfully improved the dissolution rate 
compared with intact valsartan.
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INTRODUCTION
Optimization of the physicochemical properties of a drug molecule 
is important in the development of solid oral dosage forms. The 
solid state properties of a drug compound such as the crystalline 
phase, amorphous, pseudopolymorph and salt will significantly 
affect the dissolution rate and bioavailability of drug compounds 
in the systemic circulation. For poorly soluble drugs, in particular, 
the dissolution process is a rate limiting step for absorption in the 
gastrointestinal tracts [1]. Some of current approaches have been 
proposed to improve the dissolution rate and bioavailability of 
drug compounds including the formation of inclusion complexes 
with β-cyclodextrin [2], the formation of eutectic mixture and co-
crystalline phase [3,4], nanoparticle formulation [5], and amorphous 
solid dispersion system [6].
Valsartan is one of poorly soluble drugs, an orally active angiotensin 
II receptor antagonist. It has been used to lower the blood pressure 
in hypertensive patients. Valsartan is classified as Class II compound 
according to the biopharmaceutical classification system with 
high permeability but low aqueous solubility with a dissolution 
rate dependent absorption [7]. The gastrointestinal absorption of 
valsartan can be enhanced by increasing its dissolution rate. Several 
methods have been proven effective to improve dissolution rate of 
valsartan including formation of self-microemulsifying system [7], 
nanosuspension [8], formation of mucoadhesive pellets [9], and 
inclusion complexes with β-cyclodextrin [2]. One attractive approach 
to increase the dissolution rate is formation of solid dispersion of 
poorly soluble drugs with some carriers such as PVP K-30, HPMC, 
and D(−) mannitol. Solid dispersion can be defined as dispersion 
of active pharmaceutical ingredients in inert carriers or matrix in 
solid state. It can be prepared by solvent, melting and co-grinding 
method [10-12].
The aim of this study was to prepare and characterize solid dispersion 
system of valsartan and D(−) mannitol using co-grinding approach, and 
to investigate the mechanisms responsible for the improved dissolution 
rate of valsartan from solid dispersion system.
MATERIALS AND METHODS
Materials
Valsartan was purchased from Baoji Guokang Bio Technology CO., Ltd 
(China). D(−)-Mannitol was obtained from Merck (Germany). All other 
chemicals and solvents were of analytical grade.
Methods
Preparation of solid dispersion
Solid dispersion system of valsartan – D(−) mannitol at various weight 
ratios (1:1, 1:3, and 1: 5) were prepared by co-grinding technique. 
The binary mixtures were ground in planetary ball milling apparatus 
(FRITSCH, pulverissete 7, Germany) for 120 minutes at 500 rpm. Co-
ground products were kept in a desiccator until further characterization.
X-ray powder diffraction analysis (XRPD)
XRP diffractograms were recorded using X-ray diffractometer (PAN 
Analytical The Netherlands). Samples were exposed to Cu-Kα radiation 
source at 40 kV and 12 mA. The diffraction patterns were obtained in 
2Ɵ range of 10-40°.
Differential scanning calorimetry (DSC) analysis
The thermal analysis was performed using TA Mettler Toledo FP90 DSC 
(Switzerland). Samples of solid dispersion and intact valsartan were 
weighed approximately 1-2 mg in aluminum pan. The heating was set 
from 50 to 250°C at a heating rate of 10°C/minute.
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Fig. 1: X-ray powder diffraction pattern of (a) intact valsartan, 
(b) D(−) mannitol, (c) solid dispersion 1:1, (d) solid dispersion 
1:3, and (e) solid dispersion 1:5
Fig. 2: Differential scanning calorimetry thermogram of (a) intact 
valsartan, (b) D(−) mannitol, (c) solid dispersion 1:1, (d) solid 
dispersion 1:3, and (e) solid dispersion 1:5
of 37±0.5°C and a stirring rate of 50 rpm. The dissolution media 
was 900 mL of aqueous phosphate buffer solution (pH 6.8). 5 mL 
of aliquot were withdrawn at designated time intervals (5, 15, 30, 
45, and 60 minutes), filtered and analyzed by ultraviolet-visible 
spectrophotometer (Shimadzu UV-1700, Japan) at λmax 250.4 nm. The 
experiment was performed in triplicate.
RESULTS AND DISCUSSION
XRPD method is most commonly used to investigate the solid state 
properties of any solid active pharmaceutical ingredients materials [3]. 
In this study, XRPD measurement was performed for each raw materials 
and solid dispersion samples. XRP diffractograms of intact valsartan 
and solid dispersions with D-mannitol are shown in Fig. 1. The presence 
of numerous characteristic peaks in the XRP diffractogram of valsartan 
in low intensity indicates that valsartan is in semicrystalline state with 
characteristic peaks appearing at a diffraction angle of 2Ɵ at 10.20, 
11.47, 13.69, 20.49, 21.76, 23.17, 26.06 (Fig. 1a). Meanwhile, D(−) 
mannitol is present as a high crystalline in nature with characteristic 
peaks appearing at a diffraction angle of 2Ɵ at 10.41, 14.58, 18.66, 
20.28, 20.91, 23.34, 28.10, 29.37, 31.67, 33.54, 38.56 (Fig. 1b). After 
preparation of solid dispersion by co-grinding with D(−) mannitol, 
characteristic peaks of valsartan were disappeared, only characteristic 
peaks of D-mannitol were exist (Fig. 1c-e). This indicated that the 
semicrystalline phase of valsartan was transformed to amorphous 
state.
Thermal analysis of DSC was performed on intact valsartan, D(−) 
mannitol, and solid dispersion system to investigate the interaction 
between valsartan and D(−) mannitol in the solid state [3]. The DSC 
thermogram of intact valsartan shows a single endothermic peak 
at 91.07°C, due to the melting of the drug. The DSC thermogram of 
D(−) mannitol exhibited a single sharp melting endothermic peak 
at 166.35°C (Fig. 2a and b). The characteristic endothermic peak 
of valsartan disappeared in all thermograms of solid dispersion 
system (Fig. 2c-e). Thus, the semicrystalline drug was embedded 
in the hydrophilic carrier and its solid state properties changed 
to amorphous one [10]. Previous studies have reported that 
disappearance of the characteristic endothermic peaks of the 
valsartan dispersed in Gelucire 50/13 is due to melting of the drug 
in the matrix [13].
SEM analysis was performed to observe the surface and crystal 
habit of different samples (intact valsartan, D(−) mannitol and 
solid dispersions system). SEM of the raw materials revealed that 
valsartan was characterized by irregular shaped crystals, whereas 
D(−) mannitol formed big polyhedral shape particles (Fig. 3a and b). 
Solid dispersions prepared by co-grinding technique represented 
a reduction of particles size of these binary mixtures (Fig. 3c-e). 
Fig. 3: Scanning electron micrographs of (a) intact valsartan, (b) D(−) mannitol, (c) solid dispersion 1:1, (d) solid dispersion 1:3, and 
(e) solid dispersion 1:5. All micrographs were taken at a magnification of ×100
a b
c d e
Scanning electron microscopy (SEM) analysis
Crystal habit observation of samples was conducted using scanning 
electron microscope (HITACHI type S-3400N, Japan). The voltage and 
current were set at 10kV and 12 mA, respectively. All samples were 
sputter-coated with a thin gold palladium layer before analysis.
In vitro dissolution rate study
In vitro dissolution rate study was conducted using USP dissolution 
apparatus type I (Hanson research SR08, USA) at a temperature 
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Fig. 4: Dissolution rate profile of intact valsartan and solid 
dispersion system prepared by co-grinding method
This indicated that cogrinding process may decrease particle size of 
valsartan in this system.
Dissolution rate profile of intact valsartan and solid dispersions are 
shown in Fig. 4. It is obvious from the figure that all solid dispersions 
of valsartan showed superior dissolution rate compared with intact 
valsartan. Solid dispersions of valsartan with D(−) mannitol in different 
ratios (1:1, 1:3, and 1:5) showed a marked enhancement in the drug 
dissolution rate, in which about 88.45%, 89.52, and 83.47% of the 
incorporated valsartan was dissolved within the first 45 minutes from 
solid dispersions, respectively. Valsartan as a poorly water soluble drug 
was embedded in the crystal lattice of D(−)mannitol during co-grinding 
process in the planetary ball mill apparatus. This strategy is a simple 
way to enhance the drug dissolution. The similar results have been 
reported for ketoprofen solid dispersion powders prepared with D(−) 
mannitol and PVP K-30 [14]. The solid state of valsartan in the carriers 
was in amorphous form and dispersed homogeneously as fine particles. 
Mechanisms suggested to be responsible for the increased dissolution 
rate of valsartan in solid dispersion system include reduction of particle 
size of valsartan, amorphization, and improved wettability of valsartan 
by hydrophilic carrier at diffusion layer [15,16].
CONCLUSION
This study clearly shows that solid dispersion of valsartan with D(−) 
mannitol prepared by co-grinding technique has successfully improved 
the dissolution rate compared with intact valsartan. Co-grinding 
process may cause a phase transformation of the semicrystalline form 
to the amorphous state.
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